Research Paper On Drug Abuse In Sports

1. Baron DA, Martin DM, Abol Magd S. Doping in sports and its spread to at-risk populations: an international review. World Psychiatry. 2007;6:118–123.[PMC free article][PubMed]

2. Catlin DH, Murray TH. Performance-enhancing drugs, fair competition, and Olympic sport. JAMA. 1996;276:231–237.[PubMed]

3. Fernandez MM, Hosey RG. Performance-enhancing drugs snare nonathletes, too. J Fam Pract. 2009;58:16–23.[PubMed]

4. Metzl JD, Small E, Levine SR, Gershel JC. Creatine use among young athletes. Pediatrics. 2001;108:421–425.[PubMed]

5. Uvacsek M, Nepusz T, Naughton DP, Mazanov J, Ranky MZ, Petroczi A. Self-admitted behavior and perceived use of performance-enhancing vs psychoactive drugs among competitive athletes. Scand J Med Sci Sports. 2011;21:224–234.[PubMed]

6. National Institute on Drug Abuse, US Department of Health and Human Services Monitoring the future national survey on drug use, 1975–2003, volume II. College students and adults ages 19–25. [Accessed June 12, 2014]. Available from:

7. Green GA, Uryasz FD, Petr TA, et al. NCAA study of substance abuse habits of college student-athletes. Clin J Sports Med. 2001;11:51–56.[PubMed]

8. Kersey RD, Elliot DL, Goldberg L, et al. National Athletic Trainers’ Association position statement: anabolic-androgenic steroids. J Athl Train. 2012;47:567–588.[PMC free article][PubMed]

9. Cottler LB, Abdallah AB, Cummings SM, Barr J, Banks R, Forchheimer R. Injury, pain, and prescription opioid use among former National Football League (NFL) players. Drug Alcohol Depend. 2011;116:188–194.[PMC free article][PubMed]

10. McDuff DR, Baron D. Substance use in athletics: a sports psychiatry perspective. Clin Sports Med. 2005;24:885–897.[PubMed]

11. Wanjek B, Rosendahl J, Strauss B, Gabriel HH. Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge and attitudes. Int J Sports Med. 2007;28:346–353.[PubMed]

12. Botre F, Pavan A. Enhancement drugs and the athlete. Phys Med Rehabil Clin N Am. 2009;20:133–148.[PubMed]

13. Morse ED. Substance use in athletes. In: Baron DA, Reardon CL, Baron SH, editors. Clinical Sports Psychiatry: An International Perspective. Oxford, UK: Wiley; 2013.

14. Reardon CL, Factor RM. A systematic review of diagnosis and medical treatment of mental illness in athletes. Sports Med. 2010;40:961–980.[PubMed]

15. Riggs P, Levin F, Green AI, et al. Comorbid psychiatric and substance abuse disorders: recent treatment research. Subst Abuse. 2008;29:51–63.[PubMed]

16. Baron DA, Reardon CL, Baron SH. Doping in sport. In: Baron DA, Reardon CL, Baron SH, editors. Clinical Sports Psychiatry: An International Perspective. Oxford, UK: Wiley; 2013.

17. Yesalis CE. History of doping in sport. In: Bahrke MS, Yesalis CE, editors. Performance Enhancing Substances in Sport and Exercise. Champaign, IL, USA: Human Kinetics; 2002.

18. Landry GL, Kokotailo PK. Drug screening in athletic settings. Curr Problems Pediatr. 2004;24:344–359.[PubMed]

19. Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic. Clin Chem. 1997;43:1262–1279.[PubMed]

20. McGann B, McGann C. The Story of the Tour de France. Indianapolis, IN, USA: Dog Ear Publishing; 2006.

21. Teale P, Scarth J, Judson S. Impact of the emergence of designer drugs upon sports doping testing. Bioanalysis. 2012;4:71–88.[PubMed]

22. International Association of Athletics Federations IAAF commitment to healthy and drug free athletic. 2013. [Accessed August 29, 2013]. Available from:

23. Federation Internationale de Football Association A brief history of doping. 2013. [Accessed August 29, 2013]. Available from:

24. International Olympic Committee Factsheet: the fight against doping and promotion of athletes’ health. 2013. [Accessed August 29, 2013]. Available from:

25. World Anti-Doping Agency A brief history of anti-doping. 2010. [Accessed August 29, 2013]. Available from:

26. Voet W. Breaking the Chain. London, UK: Random House; 1999.

27. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335:1–7.[PubMed]

28. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281:E1172–E1181.[PubMed]

29. Storer TW, Magliano L, Woodhouse L, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab. 2003;88:1478–1485.[PubMed]

30. Wallace MB, Lim J, Cutler A, Bucci L. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc. 1999;31:1788–1792.[PubMed]

31. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol. 1998;49:421–432.[PubMed]

32. Kohler M, Thomas A, Geyer H, Petrou M, Schanzer W, Thevis M. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009. Drug Test Anal. 2010;2:533–537.[PubMed]

33. Handelsman DJ. Clinical review: the rationale for banning human chorionic gonadotropin and estrogen blockers in sport. J Clin Endocrinol Metab. 2006;91:1646–1653.[PubMed]

34. Handelsman DJ. Indirect androgen doping by oestrogen blockage in sports. Br J Pharmacol. 2008;154:598–605.[PMC free article][PubMed]

35. Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab. 2010;95:1533–1543.[PubMed]

36. Meinhardt U, Nelson AE, Hansen JL, et al. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann Intern Med. 2010;152:568–577.[PubMed]

37. Holt RI, Sonksen PH. Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol. 2008;154:542–556.[PMC free article][PubMed]

38. Eichner ER. Stimulants in sports. Curr Sports Med Rep. 2008;7:244–245.[PubMed]

39. Higgins P, Tuttle TD, Higgins CL. Energy beverages: content and safety. Mayo Clin Proc. 2010;85:1033–1041.[PMC free article][PubMed]

40. National College Athletic Association NCAA guidelines to document ADHD treatment with banned stimulant medications. Addendum to the Jan 2009 guideline. 2010. [Accessed June 12, 2014]. Available from:

41. Shaikin B. Los Angeles Times. Baseball’s 2008 drug test results released in report. Jan 10, 2009. [Accessed September 17, 2010]. Available from:

42. Judkins C, Prock P. Supplements and inadvertent doping – how big is the risk to athletes. Med Sports Sci. 2012;59:143–152.[PubMed]

43. Kendall KL, Smith AE, Graef JL, et al. Effects of four weeks of high-intensity interval training and creatine supplementation on critical power and anaerobic working capacity in college-aged men. J Strength Cond Res. 2009;23:1663–1669.[PubMed]

44. Branch JD. Effect of creatine supplementation on body composition and performance: a meta-analysis. Int J Sport Nutr Exerc Metab. 2003;13:198–226.[PubMed]

45. Elliott S. Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. Br J Pharmacol. 2008;154:529–541.[PMC free article][PubMed]

46. Bailey JA, Averbuch RN, Gold MS. Cosmetic psychiatry: from Viagra to MPH. Directions in Psychiatry. 2009;29:1–13.

47. Kindermann W. Do inhaled beta(2)-agonists have an ergogenic potential in non-asthmatic competitive athletes? Sports Med. 2007;37:95–102.[PubMed]

48. Davis E, Loiacono R, Summers RJ. The rush to adrenaline: drugs in sport acting on the beta-adrenergic system. Br J Pharmacol. 2008;154:584–597.[PMC free article][PubMed]

49. Bougault V, Boulet LP. Is there a potential link between indoor chlorinated pool environment and airway remodeling/inflammation in swimmers? Expert Rev Respir Med. 2012;6:469–471.[PubMed]

50. World Anti-Doping Agency The World Anti-Doping Code: The 2013 Prohibited List International Standard. 2013. [Accessed August 23, 2013]. Available from:

51. Petroczi A, Naughton DP. Potentially fatal new trend in performance enhancement: a cautionary note on nitrate. J Int Soc Sports Nutr. 2010;7:25.[PMC free article][PubMed]

52. Watson P, Hasegawa H, Roelands B, Piacentini MF, Looverie R, Meeusen R. Acute dopamine/noradrenaline reuptake inhibition enhances human exercise performance in warm, but not temperate conditions. J Physiol. 2005;565(Pt 3):873–883.[PMC free article][PubMed]

53. Schmitt L, Millet G, Robach P, et al. Influence of “living high-training low” on aerobic performance and economy of work in elite athletes. Eur J Appl Physiol. 2006;97:627–636.[PubMed]

54. Vardy J, Judge K. Can knowledge protect against acute mountain sickness? J Public Health. 2005;27:366–370.[PubMed]

55. Suedekum NA, Dieff R. Iron and the athlete. Curr Sports Med Rep. 2005;4:199–202.[PubMed]

56. Maughan RJ, Shirreffs SM. Nutrition for sports performance: issues and opportunities. Proc Nutr Soc. 2012;71:112–119.[PubMed]

57. Koshy KM, Griswold E, Schneeberger EE. Interstitial nephritis in a patient taking creatine. N Engl J Med. 1999;340:814–815.[PubMed]

58. Edmunds JW, Jayapalan S, DiMarco NM, Saboorian MH, Aukema HM. Creatine supplementation increases renal disease progression in Han:SPRD-cy rats. Am J Kidney Dis. 2001;37:73–78.[PubMed]

59. Saugy M, Avois L, Saudan C, et al. Cannabis and sport.


In a bid to improve performance and/or aid recovery, various pharmaceutical products have been used, both openly (legally) and in a clandestine manner against the rules of governing bodies, by a broad array of athletes.1 The World Anti-Doping Agency (WADA) strictly regulates the use of pharmaceutical products in competitive sport. WADA produced and regularly updates the World Anti-Doping Code that includes a prohibited drug list. This list dictates what is and is not acceptable, from a doping perspective, within sport (table 1). The list has various subsections with some drugs banned both ‘in’ and ‘out’ of competition, while others are banned ‘in’ competition only (eg, ephedrine and the cannabinoids). The WADA list of prohibited substances is further broken down into several subcategories of specific products, including anabolic agents, peptide hormones and growth factors; β-2 agonists; hormone and metabolic modulators; diuretics and masking agents; stimulants; narcotics; cannabinoids; and glucocortocosteroids (table 1). Despite strict rules and punishments being in place in an attempt to limit doping offences, there continues to be those who choose to try and gain an unfair advantage in sport by taking drugs.3

As well as the concerns of WADA in defending the spirit of free and fair competition, awareness is also raised when there are known health consequences of drug abuse. The negative health consequences of doping for athletes and the education of support staff are the focus of this narrative review. Clearly, doping and athlete health is a vast area and so two points of delimitation are made up-front. First, we concentrate on cardiovascular (CV) health consequences of drug use. Second, this review focuses on anabolic agents and stimulants. According to WADA's adverse analytical findings report from 2010, anabolic agents accounted for around 60% of adverse findings, with stimulants contributing around 10%.4 Consequently, the clinical support teams working with athletes must understand the potential CV health consequences when athletes abuse these drugs. Finally, we will discuss the CV effects of cocaine use, as it is one of the most widely used recreational drugs detected in athletes.4 As well as reflecting on previous data related to the CV health consequences of anabolic steroid, stimulant and cocaine use we have attempted to provide extra context and information in the form of brief case-study exemplars on anabolic steroid and cocaine abuse.

Table 1

WADA prohibited substance list (Adapted from WADA 2012 Prohibited List2)

Anabolic agents

There are a number of drugs that are used in an attempt to increase lean muscle mass. Of these, the most well known is the steroid hormone testosterone (T) and the various analogues that are based around testosterone, usually referred to as androgenic anabolic steroids (AS). In addition to AS there are non-steroid agents that are used in an attempt to generate the same anabolic effects. These include the β-2 agonist, clenbuterol (which is additionally used as an anorectic agent to reduce body fat), human growth hormone (HGH) and insulin/insulin-like growth factors. Other growth factors are commonly used in between courses of anabolic agent use and these include human chorionic gonadotropin (HCG) and erythropoietin (EPO) and more recently selective androgen receptor modulators. Whatever the classification, the purpose of anabolic and growth factors is to stimulate skeletal muscle growth and promote rapid recovery following intensive training. From a clinical perspective it is also worth noting that EPO is predominantly used to boost endurance exercise performance and in general has not crossed over to amateur and recreational sports performers. AS, HGH, HCG and insulin/insulin-like growth factors, however, are routinely used by professional, amateur and recreational athletes.5 Consequently, the likelihood of clinicians coming across users of these particular drugs is much greater.

It is worthy to note that the classification of AS covers a number of structural variants. Classically, AS are classified as water-soluble orally active forms (17-α-alkylated) and lipid-soluble parenteral forms (17-β-esterified). In addition, they are often also classified as either testosterone-based, dihydrotestosterone-based (DHT) or 19-nortestosterone-based (Nandrolone) all of which have differing properties and expected side effects. The situation is further complicated by belief among users, often stemming from anecdotal advice, that some AS are better for predominantly ‘bulking’ (eg. Deca-Durabolin) while others are better suited to losing body fat or ‘cutting’ (eg. Winstrol). Users will often use these different forms of AS in varying quantities. The use of AS is also characterised by periods of use followed by periods of abstinence, or ‘cycles’. This helps to maximise the effects of the drugs while also limiting the negative consequences and allowing the body to normalise following an ‘on’ cycle. Furthermore, users will often supplement their cycles with additional pharmaceutical agents both when bulking (eg, Insulin, human growth hormone) and when losing body fat (clenbuterol, cytomel, 2,4, dinitrophenol). Finally, there are a surprising number of drugs used to attempt to limit side effects of AS use or normalise the hypothalamo-pituitary-gonadal (HPG) axis following an AS cycle. These include estrogen receptor antagonists (tamoxifen), selective estrogen receptor inhibitors (clomifene), aromatase inhibitors (arimidex), 5-α reductase inhibitors (finesteride) and HPG axis stimulators such as HCG.

Evidence of athlete use of AS has been available since the 1950s with AS contributing to c. 60% of adverse findings according to recent WADA reports.6 In the general population there are data showing an increase in the prevalence of AS use.7 Despite such widespread use there is still some controversy as to the CV health consequences of taking AS.8 Large sample epidemiological evidence of the CV health consequences of long-term AS use is lacking, likely because of the reluctance to admit use and/or possession. In addition, evidence for a link between AS use and CV disease outcomes or end-points is mostly limited to case study reports. Published case studies include AS use associated with myocardial infarction,9 stroke,10 embolism11 and other CV health issues (table 2). Although caution should be expressed in implying cause and effect from case studies,8 they can provide direction for case series and experimental studies as well as informing/educating clinical practitioners.

Significant research attention has focused on the impact of AS use on CV disease risk factors namely blood pressure, lipid profile, left ventricular (LV) mass, cardiac function and arterial function. Elevated systemic arterial blood pressure is associated with an increased CV disease risk. Compared to healthy controls, AS users have increased resting22,26 and exercise22 systolic blood pressure. Conversely, other studies have not observed increased blood pressure in AS user.6,24 Differences in the training level of the participants along with age could be responsible for the differences seen in these studies.

AS have also been associated with negative alterations in lipid profiles.27 Changes reported include a decrease in high-density lipoprotein (HDL),28 an elevation in low-density lipoprotein (LDL)24 and reduced apolipoprotein levels,29 possibly through up-regulation of hepatic triglyceride lipase.30 The changes in lipid profiles indicate an increase in atherosclerotic risk. Increases in homocysteine, a naturally occurring amino-acid thought to have a role in vaso-control, and C-reactive proteins (CRP), an acute-phase protein that rises in response to inflammation, have been implicated as risk factors for CV disease. Grace and Davies25 demonstrated a significant increase in CRP in AS users. While Zmuda et al31 observed no significant increases in homocysteine in a group of AS users, Graham et al32 noted a significant elevation in homocysteine in AS users as well as those who had abstained from AS use for 3 months, indicating a possible effect of AS on vitamin B absorption. Previous studies have also suggested a possible link between AS use and thrombotic risk through alterations in haemoglobin levels.33

An increase in LV mass is an independent risk factor for CV disease.34 AS use has been associated with an increase in LV mass,35,36 but there is conflicting data.27,37,38 There are some data in AS users that suggest a reduction in systolic cardiac function38 although this is not a consistent finding between studies.8 A reduction in diastolic function has been observed more frequently and it has been suggested that a reduction in myocardial relaxation/elastance is associated with AS use.27,37,38 AS use has also been associated with reduced endothelial function in conduit arteries.6,24,39 Ebenbichler et al40 and Sader et al6 noted a reduced flow-mediated dilation in AS users as well as a reduced vasodilator response to glyceryl-trinitrate.

There is a growing evidence base that AS use can have a negative effect on multiple CV disease risk factors. We present a case study exemplar to illustrate the broad effect of AS use on the CV system.

Case study 1

A 25-year-old bodybuilder who was enrolled into a research study gave a detailed history of prolonged AS use. He self-reported no cardiac health problems. The participant was 1.93 m and 127 kg with an LV mass of 218 g on cardiac MRI. While absolute LV mass was high this was normalised when indexed for fat free mass. Left ventricular (LV) ejection fraction was normal (63%), while right ventricular (RV) ejection fraction was slightly reduced at 49%. LV diastolic function, measured using ultrasound echocardiography, was moderately depressed (significant increases in late atrial filling and tissue velocities). Heart rate was 75 beats per min and the ECG was unremarkable. Blood pressure was 131/71 mm/Hg. Total cholesterol was within normal clinical limits (4.6 mmol/l), but high-density lipoproteins were significantly reduced in the participant at 0.46 mmol/l. Low-density lipoproteins were above clinically acceptable levels at 3.77 mmol/l. The participant had an elevated level of alanine transaminase indicative of reduction in liver function. In addition, both testosterone and sex-hormone binding globulin were well below those expected within a male, at 2.13 and 6 nmol/l, respectively. Gamma glutamyltransferase was not assessed. Based on changes to numerous CV risk factors, this athlete was informed of the test outcomes and was directed to seek a general practitioner consultation.

While recent data have started to paint a clearer picture of some of the negative CV consequences of AS use, longitudinal data are still lacking making the long-term chronic effects of AS use difficult to ascertain.8 There is also uncertainty in relation to the impact of withdrawal of AS use on CV risk factors. Inherently, the study of AS use is complicated by many factors. Specifically, most studies recruit diverse cohorts of self-selected AS users. In these groups there is likely great heterogeneity in total AS dose, poly-drug regimens employed as well the difficulty in verifying the ‘true’ dosages used.8

There is little direction given to clinicians and health practitioners regarding the identification of clandestine AS use. One of the reasons for athletes engaging in illicit AS use is that there are few ‘tell tale’ signs particularly in those sports where elevated strength and/or fat free mass is relatively commonplace. AS use occurs predominantly but not exclusively in strength and/or power athletes. Of the nine adverse findings for AS by the UK Anti-Doping Agency, three were from professional rugby players.41 It is worth noting that clinicians are far more likely to encounter recreational athletes using AS, training for predominantly aesthetic purposes. AS users may have rapid increases in lean mass, excessive hypertrophy of the trapezius, the shoulder musculature42 and a large neck circumference43 possibly due to higher androgen receptor levels.41 Other signs of AS use include puffy swelling around the face42 and acne which occurs in approximately 50% of users (including acne fulminans and acne conglobata).44 Consequently, clinicians may be suspicious of AS use in muscular individuals with acne (and/or scarring from previous eruptions) extending beyond the face to the back, chest and upper arms.44. Another common side effect of AS use is the development of female breast tissue (gynaecomastia) because of the aromotisation of AS to estrogen. The size and rate of development will vary depending on the type and duration of AS exposure with cases ranging from small areas of puffy tissue behind the nipple to easily recognisable breast tissue. It must be stressed however that these are general signs that may indicate AS use, but clinicians should be wary of unfairly targeting individuals who are simply prone to acne, or have a genetic basis for a muscular shoulder girdle.

Table 2

Cardiovascular events and risk factors from AS use


Stimulants consist of psychoactive drugs, including amphetamines and its derivatives, as well as cocaine, caffeine and nicotine and are used to increase psychological activity, thereby inducing improvements in mental aptitude, physical function or both. Stimulants used for performance enhancement are typically those that affect the central nervous system (CNS); however, concurrent effects on the CV system are common. Amphetamines affect the CNS and autonomic nervous systems causing tachycardia and vasoconstriction as well as having psychological effects, increasing mental alertness and decreased fatigue. Cocaine has similar affects to amphetamines and also exerts its effect through the CNS causing an increase in the release of catecholamines, such as norepinephrine, as well as causing an increase of circulating dopamine. Ephedrine and its isomers are sympathomimetic agonists at both α- and β-adrenergic receptors and also have potent CV effects including increasing heart rate and blood pressure through vasoconstriction. The CV effects of stimulants have been shown to have a detrimental effect on CV health.45

There have been numerous reported cases of serious adverse CV events, including fatalities, linked with the use of ephedrine's.46,47 The use of ephedrine has also been linked to cardiomyopathy48 and stroke49 while pseudoephedrine use has also been linked with stroke50 and coronary artery spasm with myocardial infarction.51 Further, there are numerous case reports of significant cardiovascular events following the administration of over-the-counter stimulants.46 As with AS use, the interpretation of such case reports is difficult, since it may be that serious adverse events are as a consequence of preexisting medical conditions combined with drug use. What case studies do promote is further experimental study. For example, doses equivalent to three to four times greater than the recommended therapeutic dose of pseudoephedrine have raised diastolic blood pressure above 90 mm Hg.52 These results were in accord with two other studies: Bye et al53 reported significant increases in heart rate and systolic blood pressure following relatively high doses of pseudoephedrine (120 and 180 mg); Empey et al54 noted that doses of 120 and 180 mg produced statistically significant increases in both pulse and systolic blood pressure. The clinical relevance of these blood pressure changes is not known.

Reports of the CV effects of sympathomimetics in therapeutic doses have been conflicting. Bye et al53 observed that a single dose of ephedrine (25 mg) significantly elevated both heart rate and systolic blood pressure while a single therapeutic dose of pseudoephedrine (60 mg) significantly elevated only systolic arterial blood pressure. Bright et al55 and Empey et al54 noted little change in CV function following therapeutic doses. Increased blood pressure has been demonstrated in cases whereby ephedrine's have been co-administered with a moderate dose of caffeine.56 Caffeine is thought to exacerbate the action of ephedrine's since it too may cause vasoconstriction through antagonism of adenosine and release of catecholamines.

All stimulants structurally related to amphetamine can cause catecholamine-mediated cardiotoxicity. Increased catecholamine levels can lead to vasoconstriction, vasospasm, tachycardia and hypertension and it is as a result of these responses that oxygen supply to the heart is compromised and hypertrophy, fibrosis and necrosis can result.57 Clearly, such conditions develop over time, as a consequence of chronic exposure to amphetamines and the repercussions may include myocardial infarction, aortic dissection and sudden cardiac death.57

Little has been done by way of measuring both the acute/chronic effects of stimulant use/abuse on a range of CV risk factors. While significant CV events are associated with their use, the effect on long-term atherosclerotic risk even with moderate usage, through negative alterations in known CV risk factors is worthy of further examination. With regard to amphetamines, emphasis has largely focused on the adverse effects relating to the CNS; however, it is clear that their effects can be wide-ranging and no less significant.

Stimulants—cocaine and others

Cocaine is one of the most frequently used recreational drugs worldwide. The prevalence of use in the UK has been steadily increasing over recent years with 6.6% of 16–24 year olds admitting to regular use and figures suggesting over 1 million current cocaine users in the UK.58 Despite limited use as a performance-enhancing drug, there is still a relatively high level of adverse findings for cocaine use in athletes. According to WADA around 11.3% of adverse findings for stimulants were as a result of cocaine use.4 Athletes are not immune to the lure of social drugs like cocaine.

The use of cocaine has been associated with acute and chronic cardiovascular disease.59,60 Cocaine inhibits norepinephrine reuptake in the sympathetic system leading to overstimulation60 and may cause release of catecholamines from central and peripheral stores.61 Acute coronary syndromes (including myocardial ischemia and infarction) are the commonest cardiac events secondary to cocaine abuse.60,61 This may be due to coronary artery spasm, increase in myocardial oxygen consumption from increases in heart rate and blood pressure, and a prothrombotic state.62,63 Most myocardial infarctions occur in the absence of atherosclerotic coronary disease and are unrelated to the dose and frequency of cocaine use.64 Cocaine abuse may however also lead to premature coronary disease sometimes with quite rapid onset.65 Cocaine abuse may also lead to coronary artery aneurysms, aortic dissection, rupture, vasculitis and stroke.66–68

Arrhythmias are not common with cocaine use, but sinus tachycardia, sinus bradycardia, supraventricular, ventricular arrhythmias and bundle branch blocks have been reported.59,69,70 A dilated cardiomyopathy can be caused by cocaine use and a cocaine-induced myocarditis has been reported at postmortem in 20–30% of cases.71 Myocarditic changes, however, may be fully reversible if identified early and abstention from further cocaine abuse occurs. In the case study detailed the ECG changes with a significant cardiac event are shown in a young professional athlete who has a cocaine abuse history.

Case study 2

We briefly describe the case of a 27-year-old professional skater with a history of cocaine abuse. He developed retrosternal chest pain and ECG changes of inferolateral ST elevation (figure 1) after taking cocaine. His symptoms settled with nitrates and he developed T-wave inversion on his ECG the following day (figure 2) with a rise in Troponin I of 18.5 µg/l. He had normal left ventricular systolic function on echocardiography. On cardiac catheterisation he had a smooth 40% stenosis in the ostial left anterior descending artery with the other coronary branches normal (figure 3). He was initially treated with antiplatelets, heparin and a β-blocker, but as it was felt that he had sustained a myocardial infarction due to coronary artery spasm, the β-blocker was substituted with a calcium channel blocker prior to discharge from hospital. He remained pain-free when further reviewed at 3 months.

Figure 1

ECG 1: inferolateral ST elevation with chest pain. This figure is only reproduced in colour in the online version.

Figure 2

ECG 2: Inferior T-wave inversion with lateral biphasic T wave. This figure is only reproduced in colour in the online version.

Figure 3

Coronary angiography: 40% stenosis in ostial left anterior descending artery (arrow) with other coronary branches normal.

While detection of cocaine use, unless openly admitted, can be problematic for the practitioner there are certain psychological and physiological indications that may help inform the healthcare provider. Cocaine use can produce euphoria, decreased appetite and need for sleep, but may also cause anxiety, irritability, paranoia and hallucinations. There may be associated tachycardia, sweating, pupil dilatation and nausea. Withdrawal after chronic use mainly causes psychological symptoms including depression, anxiety and increased sleep.

Other common stimulants used by athletes include caffeine and nicotine (from smoking tobacco, chewing tobacco and smoking cessation products). Both caffeine and nicotine have been shown to have cardiac effects. Caffeine is used by athletes as a stimulant to decrease the feelings of fatigue and elevate heart rate and neural activity. The effect of caffeine will increase myocardial O2 and has been shown to increase blood pressure as well as raises the level of free-fatty acids in the blood, thereby increasing blood viscosity. If used in moderate doses there are minimal long-term side effects to caffeine use; however, extremely high doses have been associated with cardiac arrhythmias72 and events in otherwise healthy individuals.73,74 Cigarette smoking has long been known to promote atherosclerosis, with an increased risk of sudden death,75 myocardial infarction76,77 and stroke.78 The use of nicotine therapies such as transdermal patches, inhalators and gum as well as the common use of chewing tobacco in some sports has also been associated with an increased cardiovascular event risk.79,80 Again, much of these data have come from case study and anecdotal data, with larger studies not observing a significant increase in risk of cardiovascular events.81 Like most other stimulants further research is required and given that both caffeine and nicotine are not completely banned admission and monitoring of use may be easier than with other drugs.


This review has attempted to describe available data and exemplar case studies detailing the potential CV health issues surrounding the use of some of the most common drugs detected in doping screens on athletes. Negative CV health effects do occur but more controlled research trials are required alongside longitudinal studies of chronic drug use. Available data demonstrate enough concern in relation to CV health and drug use that healthcare practitioners should be fully educated to help detect signs and symptoms and support athlete treatment and recovery where appropriate.


Leave a Comment


Your email address will not be published. Required fields are marked *